COMPARISON HYPOXIA, GLUCOSE UPTAKE RAT R3230 TUMORS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定是研究者机构。目标#1使用校准的缺氧标志物EF 5测定肿瘤中的体内缺氧标志物Cu（64）-ATSM。使用microPET和免疫组织化学比较这两种标记物在肿瘤中的分布和数量。 目标#2比较血氧水平依赖性成像（BOLD）的信号，如MRI所确定的，与Cu（64）-ATSM-PET的信号。 目标#3比较（18）FDG的体内摄取与肿瘤中葡萄糖的分布，如通过肿瘤冷冻切片中的成像生物发光所测量的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Goal #1 Validate the in-vivo hypoxia marker Cu(64)-ATSM in tumors using the calibrated hypoxia marker EF5. The two markers are to be compared concerning their distribution and their amount in the tumor, using microPET and immunohistochemistry. Goal #2 Compare the signal of blood-oxygen-level-dependent imaging (BOLD), as determined with MRI, with the signal of Cu(64)-ATSM-PET. Goal #3 Compare the in-vivo uptake of (18)FDG with the distribution of glucose in the tumor, as measured by imaging bioluminescence in cryosections of tumors.